Oral Anti Diabetic Agents in the Hospital

Use of Oral Antidiabetic Agents in Hospitalized Patients With Diabetes

This randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in the management of diabetes in the hospital. The primary outcome of the study is to determine differences in glycemic control as measured by mean daily blood glucose concentration between oral antidiabetic medications and basal bolus therapy in hospitalized patients with type 2 diabetes (T2D).

Study Overview

• Status: Recruiting
• Conditions: Diabetes Mellitus
• Intervention / Treatment: Drug: Oral Anti-diabetes Drugs alone; Drug: Supplemental insulin; Device: Continuous glucose monitoring (CGM); Drug: Basal bolus insulin

Detailed Description

Hyperglycemia in the hospital is common and has been associated with increased hospital complications, length of stay, and mortality. Improving glycemic control has been shown to improve length of stay, multi-organ failure, systemic infections, as well as short- and long-term mortality. Clinical guidelines from professional organizations recommend the use of subcutaneous (SQ) insulin as the preferred therapy for glycemic control in general medical and surgical patients with T2D. This approach, however, is labor intensive requiring multiple daily insulin injections, costly, and associated with significant risk of iatrogenic hypoglycemia

Over 75% of patients with T2D are treated with oral antidiabetic drugs (OADs) but due to the lack of safety and efficacy data from randomized controlled trials, clinical guidelines recommend stopping OADs during hospitalization. The current clinical guidelines have raised concerns with the use of OADs including risk of hypoglycemia with sulfonylureas, fluid retention and worsening of heart failure with thiazolidinediones, and risk of metformin-associated lactic acidosis in patients with severe renal impairment. However, several observational studies have reported that the use of OADs results in similar glycemic control without increased risk of complications compared to insulin regimens. A recent observational study that included 17,325 hospitalized patients with T2D, found that patients treated with OADs had similar glycemic control without differences in complications and no increase in rates of hypoglycemia compared to those treated with insulin.

This study will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in the management of diabetes in hospital patients with T2D. For a subset of participants (50 patients per group), a CGM devise will be placed for the duration of the study to assess parameters of glycemic control and hypoglycemia.

• Study Type: Interventional
• Enrollment (Estimated): 260
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Maya Fayfman, MD; Phone Number: 404-778-1664; Email: maya.fayfman@emory.edu

Study Locations

• United States
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Recruiting
      • Emory University Hospital
      • Contact: Maya Fayfman, MD; Phone Number: 404-778-1664; Email: maya.fayfman@emory.edu
    • Atlanta, Georgia, United States, 30322
      • Recruiting
      • Emory University Hospital Midtown
      • Contact: Maya Fayfman, MD; Phone Number: 404-778-1664; Email: maya.fayfman@emory.edu
    • Atlanta, Georgia, United States, 30322
      • Recruiting
      • Grady Memorial Hospital
      • Contact: Maya Fayfman, MD; Phone Number: 404-778-1664; Email: maya.fayfman@emory.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Males or females, age 18-80 years admitted to a general medicine and surgery services
• Known history of T2D receiving OADs either as monotherapy or in combination therapy
• Admission BG < 250 mg/dl or randomization BG <250 mg/dl and not receiving basal insulin
• Patients receiving OADs in combination with GLP-1 receptor agonists (GLP-1RA) who have HbA1c <7.5% within the past three months
• HbA1c <10%

Exclusion Criteria:

• No known history of diabetes
• Laboratory evidence of diabetic ketoacidosis
• Subjects with a history of type 1 diabetes (suggested by BMI < 25 requiring insulin therapy or with a history of diabetic ketoacidosis, or ketonuria)
• Meeting any exclusion criteria based on specific contraindications to their home oral therapy
• Acute critical illness or cardiac surgery expected to require admission to a critical care unit
• Gastrointestinal obstruction, adynamic ileus, or expected to require gastrointestinal suction
• Medical or surgical patients expected to be kept NPO for >24-48 hours after admission or after completion of surgical procedure
• Impaired renal function (eGFR <30 ml/min)
• Current treatment with oral or injectable corticosteroid
• Mental condition rendering the subject unable to understand the nature and scope of the study
• Female subjects who are pregnant or breastfeeding at time of enrollment in the study
• New or recent onset (within two weeks) of coronavirus disease 2019 (COVID-19) infection at the time of admission

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Oral Anti-diabetes Drugs (OADs) alone; OADs will be continued at same outpatient dosage unless contraindicated	Drug: Oral Anti-diabetes Drugs alone; OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.; Other Names: pioglitazone; metformin; sulfonylureas; dipeptidyl peptidase-4 (DPP-4) inhibitors; sodium-glucose co-transporter 2 (SGLT2) inhibitors; Drug: Supplemental insulin; Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG >140 mg/dl.; Other Names: Humalog; Novolog; Device: Continuous glucose monitoring (CGM); A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment. The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes.; Other Names: Dexcom
Active Comparator: Basal bolus insulin; Basal insulin with glargine or detemir and rapid-acting insulin (lispro/aspart) will be used as per the hospital formulary. OADs and non-insulin injectable antidiabetic medication will be discontinued on admission.	Drug: Supplemental insulin; Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG >140 mg/dl.; Other Names: Humalog; Novolog; Device: Continuous glucose monitoring (CGM); A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment. The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes.; Other Names: Dexcom; Drug: Basal bolus insulin; Basal insulin with glargine or detemir will be used as per the hospital formulary.; Other Names: glargine; detemir

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean daily BG concentration	Mean daily BG concentration will be compared between OADs and basal bolus therapy in hospitalized patients with T2D.	During hospital stay (up to 10 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of mild hypoglycemic events	Mild hypoglycemic events are defined as BG <70 mg/dl. Hypoglycemic events are assessed by point of care (POC) testing and continues glucose monitoring (CGM).	During hospital stay (up to 10 days)
Number of clinically significant hypoglycemic events	Clinically significant hypoglycemic events are defined as BG <54 mg/dl. Hypoglycemic events are assessed by POC testing and CGM.	During hospital stay (up to 10 days)
Number of severe hypoglycemic severe (<40 mg/dl) events	Severe hypoglycemic events are defined as BG <40 mg/dl. Hypoglycemic events are assessed by POC testing and CGM.	During hospital stay (up to 10 days)
Percent of BG within target range without hypoglycemia	The percentage of BG values within the target range of 70-180 mg/dl and without hypoglycemia will be compared between study arms.	During hospital stay (up to 10 days)
Number of episodes of hyperglycemia after the first day of treatment	The number of episodes of hyperglycemia (BG > 280 mg/dl) after the first day of treatment will be compared between study arms.	During hospital stay (up to 10 days)
Daily dose of insulin	The total daily dose of insulin will be compared between study arms.	During hospital stay (up to 10 days)
Number of patients using oral antidiabetic drugs (OADs) during hospitalization	The number of participants using OADs during hospitalization use will be recorded.	During hospital stay (up to 10 days)
OAD dose used during hospitalization	Dosage of OADs used during hospitalization will be recorded.	During hospital stay (up to 10 days)
Number of patients on OADs requiring insulin rescue therapy	The number of patients on OADs requiring insulin rescue therapy will be recorded	During hospital stay (up to 10 days)
Number of episodes of treatment failure	Treatment failure is defined as mean daily BG > 240 mg/dl or 3 consecutive BG > 240 mg/dl.	During hospital stay (up to 10 days)
Glycemic variability in participants receiving CGM monitoring	Glycemic variability will be measured using the coefficient of variation	During hospital stay (up to 10 days)
Time above BG target range (>180 mg/dl) in participants receiving CGM monitoring	The percentage of time above BG target range (>180 mg/dl) will be assessed in participants receiving CGM monitoring.	During hospital stay (up to 10 days)
Time in BG target range (70-180 mg/dl) in participants receiving CGM monitoring	The percentage of time in the BG target range (70-180 mg/dl) will be assessed in participants receiving CGM monitoring.	During hospital stay (up to 10 days)
Time below BG target range (BG <70 mg/dl) in participants receiving CGM monitoring	The percentage of time below BG target range (BG <70 mg/dl) will be assessed in participants receiving CGM monitoring.	During hospital stay (up to 10 days)
Number of hospital complications	Hospital complications is assessed as a composite variable including infectious, renal, pulmonary, neurologic, cardiovascular complications, and mortality.	During hospital stay (up to 10 days)
In-hospital mortality	In-hospital mortality will be recorded will be compared between study arms.	During hospital stay (up to 10 days)
Number of individual hospital complications	Number of individual hospital complications will be compared between study arms. The specific complications assessed for this outcome include acute respiratory failure, acute renal failure (incremental rise in creatinine by 0.5 mg/dL from baseline), infection during hospitalization not felt to be present on admission (including wound infection, urinary tract infection, bacteremia), myocardial infarction, cardiac arrhythmia, congestive heart failure, and cardiac arrest.	Up to 40 days (hospital stay plus 30 days after discharge)
Hospital costs	Total hospital costs will be compared between study arms.	During hospital stay (up to 10 days)
Length of hospital stay	Length of hospital stay, in days, will be compared between study arms.	During hospital stay (up to 10 days)
Costs for diabetes specific therapies	Costs for diabetes specific therapies (including insulin, oral agents, and cost of injection administration) will be compared between study arms.	During hospital stay (up to 10 days)
Number of hospital re-admissions	Number of hospital re-admissions within 30 days of hospital discharge will be compared between study arms.	within 30 days of hospital discharge
Number of emergency room visits	Number of emergency room visits within 30 days of hospital discharge will be compared between study arms.	within 30 days of hospital discharge
Number of participants requiring ICU care	The number of participants transferred to the ICU will be compared between study arms.	During hospital stay (up to 10 days)
Nursing antihyperglycemic drug preference survey	The nurse who provided the most care for the participant during hospitalization completed a 7-item survey assessing antihyperglycemic drug preference. Nurses indicate if they agree or disagree with statements related to patient outcomes, workload requirements of insulin therapy, and perceived usefulness and safety of OADs. A summary score is not calculated for this qualitative survey.	Day of hospital discharge (up to 10 days)
Patient antihyperglycemic drug preference survey	Participants will complete a 2 to 5-item survey assessing preferences of antihyperglycemic medications while hospitalized. Participants indicate if they agree or disagree with statements about OAD and insulin use during hospital stays, timely administration of insulin, and concerns about low blood sugar. A summary score is not calculated for this qualitative survey.	Day of hospital discharge (up to 10 days)

Collaborators and Investigators

• Sponsor: Emory University
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Investigators: Principal Investigator: Maya Fayfman, MD, Emory University

Study record dates

Study Major Dates

• Study Start (Actual): August 7, 2020
• Primary Completion (Estimated): September 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: June 2, 2020
• First Submitted That Met QC Criteria: June 2, 2020
• First Posted (Actual): June 4, 2020

Study Record Updates

• Last Update Posted (Actual): June 5, 2023
• Last Update Submitted That Met QC Criteria: June 2, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: Hyperglycemia; Hospitalization; Insulin therapy; Oral therapy; Basal bolus therapy; Mean daily blood glucose
• Additional Relevant MeSH Terms: Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protease Inhibitors; Insulin; Insulin, Globin Zinc; Metformin; Pioglitazone; Dipeptidyl-Peptidase IV Inhibitors
• Other Study ID Numbers: IRB00117027; 1K23DK124647-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be available for sharing.
• IPD Sharing Time Frame: Individual participant data will be made available for sharing beginning 3 months and ending 5 years following article publication.
• IPD Sharing Access Criteria: Individual participant data will be made available for sharing to researchers who provide a methodologically sound proposal. The proposal should be directed to maya.fayfman@emory.edu. To gain access, data requestors will need to sign a data access agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No